From what we see, these restrictions could soon turn out to be a very costly strategy from care as well as cost perspective
GLP-1 receptor agonist industry include Novo Nordisk A/S, Eli Lilly and Company, Amneal Pharmaceuticals LLC, Sanofi, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Viking Therapeutics, Structure Therapeutics, Inc., Altimmune, Sandoz Group AG, and Biocon
Some are also approved for a liver condition known as metabolic dysfunction-associated steatohepatitis (MASH)
Unfortunately, there isnt a one-size-fits-all answer, and insurance coverage depends on a few factors
Think of it as a compounding effect